Foundayo™ (orforglipron), Eli Lilly’s once‑daily oral GLP‑1 receptor agonist, was FDA‑approved on April 1, 2026 for chronic weight management in adults with obesity or overweight plus at least one weight‑related comorbidity. It is the first oral GLP‑1 that can be taken without food or water restrictions, differentiating it from earlier oral peptide GLP‑1s. Approval was granted under Priority Review via the Commissioner’s National Priority Voucher, just 50 days after filing.
In Phase III ATTAIN trials (>4,500 patients), the highest dose produced ~12.4% average weight loss (≈27 lbs) at 72 weeks, along with improvements in cardiometabolic risk factors. Foundayo™ launched April 6, 2026 with multiple dosage strengths available. Pricing is not finalized, though Lilly indicates self‑pay options may start at $149/month for the lowest dose.
